JSPR compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

JSPRJasper Therapeutics, Inc.

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

JSPRJasper Therapeutics, Inc.

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

JSPR1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±51.4%▲+6.59%×0.13

AMGN

4 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±3.7%▲+3.73%×1.00

Q2 FY26±4.1%▲+4.57%×1.12

= impliedJSPR realized, solidAMGN realized, hatchedOne scale, both sides: full bar = 52%× = |realized| ÷ impliedSource: market data

Q1 FY26

±3.9%

▼−4.75%

×1.23

Feb 4 '26±3.7%▲+8.15%×2.22

JSPRJasper Therapeutics, Inc.

16.61▲+18.00%· post 17.08

Mkt cap$16.1MRevenue—Revenue—

AMGNAmgen Inc

460.55▲+0.06%· post 460.42

ClosedNov 6 '26

Mkt cap$249.0BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

Compare

ClosedNov 6 '26

JSPRJasper Therapeutics, Inc.

AMGNAmgen Inc

16.61▲+18.00%post 17.08

Price

460.55▲+0.06%post 460.42

$16.1M

Mkt cap

$249.0B

—

Revenue

$10.4BQ3 FY26

—

Revenue

$36.8BFY25

JSPR16.61▲+18.00%vsAMGN460.55▲+0.06%ClosedNov 6 '26